<DOC>
	<DOCNO>NCT01329900</DOCNO>
	<brief_summary>The goal clinical research study learn possible collect stem cell ofatumumab chemotherapy treatment . This study also evaluate side-effects , number stem cell collect , number procedure need collect enough stem cell .</brief_summary>
	<brief_title>Chemotherapy Plus Ofatumumab Followed G-CSF Mobilization Peripheral Blood Stem Cells Patients With Non-Hodgkin 's Lymphomas</brief_title>
	<detailed_description>The Study Drugs : Ofatumumab human monoclonal antibody CD20 protein design bind surface white blood cell ( B-cells ) . It destroy cancer cell come B-cells , use treat cancer B-cells resistant CLL ( chronic lymphocytic leukemia ) . Etoposide design slow stop growth cancer cell . Filgrastim promote growth white blood cell , help fight infection . Ifosfamide design slow stop growth cancer cell . Mesna drug protects bladder cell damage chemotherapy drug ifosfamide . It use decrease risk bleed bladder . Treatment Administration : You admit hospital . You stay hospital 4-6 day part treatment . On Day 1 , receive ofatumumab CVL 6-8 hour . On Days 2 , 3 , 4 , receive ifosfamide mesna continuously etoposide every 12 hour . Mesna give help decrease risk develop side effect . As outpatient , receive high dose ofatumumab ( 1 week first one ) CVL 10-12 hour . Beginning Day 6 , get G-CSF ( filgrastim ) injection ( give skin ) continue give enough stem cell collect . Tests Procedures : Every day hospital , physical exam ask side effect may . After long hospital , physical exam ask side effect may doctor think need . While wait enough stem cell collect , blood drawn ( 1 tablespoon ) routine test least 3 time week . If doctor think need , may blood drawn often . Stem Cell Collection : Blood stem cell collect blood count return normal ( 10-16 day chemotherapy ) . The process stem cell collection take 4 hour time . You stem cell collect day enough collect ( 1-6 session ) . A machine attach CVL blood withdrawn . The blood flow machine , remove stem cell blood . The blood return back CVL . The stem cell frozen store . These stem cell give back next phase treatment help blood count recover high dose chemotherapy . After enough stem cell collect , admit hospital high dose chemotherapy . You sign separate consent receive high dose chemotherapy . During stem cell collection , blood ( 2 teaspoon ) draw CVL check cell marker affect response cell count check status disease . Length Study : Patients follow 12 month transplant . You take study early stem cell collection work . This investigational study . Etoposide ifosfamide FDA approve commercially available lymphoma . Ofatumumab approve FDA treatment recurrent refractory chronic lymphocytic leukemia . G-CSF Mesna FDA approve commercially available . The use Ofatumumab collection stem cell investigational . Up 50 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients histologically confirm CD20 positive Bcell NHL candidate autologous SCT . 2 . Patients must PR salvage chemotherapy . 3 . Age 1870 year . 4 . Platelet count &gt; /= 100,00 mm³ independent transfusion support . 5 . Absolute neutrophil count &gt; /= 1500/mm³ . 6 . Zubrod performance status ( PS ) 2 less . 7 . Negative serum pregnancy test woman childbearing potential . This female postmenopausal least 12 consecutive month undergone previous surgical sterilization . 8 . Less 5 % marrow involvement NHL within 4 week study define unilateral bone marrow aspiration biopsy . 9 . Seronegativity HIV , HTLV1 , Hepatitis . 1 . Subjects current active hepatic ( ( HbsAg , HbcAb , positive viral load PCR ) biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) ALT &gt; 2x upper limit normal bilirubin &gt; 1.5 . ( Consult physician experience care management subject hepatitis B manage/treat subject antiHBc positive . ) 2 . Active CNS disease . 3 . Severe concomitant medical psychiatric illness . 4 . Lactating breast feeding female . 5 . Serum creatinine &gt; 1.6 mg/dl . 6 . History pelvic radiation . 7 . Fludarabinebased chemotherapy within 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Stem Cell Collection</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Arzerra</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Apheresis</keyword>
</DOC>